Original data (with adjusted standard errors for multi-arm studies):

              treat1     treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
2            placebo   zolpidem -0.3035 0.1318     0.1318     0.2373     2         
6        eszopiclone    placebo -0.4039 0.1026     0.1026     0.2224     2         
10           placebo   zolpidem  0.5490 0.1099     0.1099     0.2259     2         
12       eszopiclone    placebo -0.2751 0.4616     0.4616     0.5020     2         
39           placebo   zolpidem  1.0495 0.1318     0.1318     0.2373     2         
45           placebo suvorexant  0.1882 0.0829     0.0829     0.2140     2         
46           placebo suvorexant  0.1352 0.0863     0.0863     0.2154     2         
58       eszopiclone    placebo -0.1985 0.0825     0.0825     0.2139     2         
59           placebo   zolpidem  0.5435 0.0672     0.0672     0.2084     2         
60           doxepin    placebo -0.3847 0.1637     0.1637     0.2564     2         
61           doxepin    placebo  0.0219 0.1482     0.1482     0.2468     2         
63           doxepin    placebo -0.2470 0.1326     0.1326     0.2378     2         
75           placebo  ramelteon -0.1058 0.0942     0.0942     0.2187     2         
77       eszopiclone    placebo -0.1832 0.1256     0.1256     0.2339     2         
83  BZD-intermediate    placebo -1.0466 0.3714     0.3714     0.4205     2         
99      daridorexant   zolpidem  0.0948 0.1444     0.1582     0.2889     3        *
99           placebo   zolpidem  0.1780 0.1827     0.3164     0.3572     3        *
99      daridorexant    placebo -0.0831 0.1444     0.1582     0.2889     3        *
105          placebo   zolpidem  0.4374 0.1435     0.1435     0.2440     2         
112          placebo   zolpidem  0.1313 0.2100     0.2100     0.2882     2         
114          placebo   zolpidem  0.2575 0.1425     0.1425     0.2434     2         
120      eszopiclone    placebo -0.1577 0.1385     0.1385     0.2411     2         
122          placebo  zopiclone -0.0800 0.3820     0.3820     0.4300     2         
128 BZD-intermediate   zolpidem -0.0270 0.1590     0.1590     0.2534     2         
132          placebo  trazodone  0.1933 0.1466     0.1788     0.3006     3        *
132        trazodone   zolpidem  0.0653 0.1487     0.1840     0.3037     3        *
132          placebo   zolpidem  0.2586 0.1464     0.1782     0.3003     3        *
136      eszopiclone    placebo -0.2875 0.0738     0.0738     0.2107     2         
137          placebo   zolpidem  0.5922 0.1428     0.1428     0.2436     2         
144      eszopiclone    placebo -0.0439 0.1220     0.1220     0.2320     2         
145          placebo  ramelteon  0.0163 0.1218     0.1218     0.2319     2         
153      lemborexant   zolpidem  0.1067 0.0772     0.0865     0.2556     3        *
153          placebo   zolpidem  0.3262 0.0955     0.1400     0.2738     3        *
153      lemborexant    placebo -0.2195 0.0841     0.0978     0.2616     3        *
154      lemborexant    placebo  0.2545 0.1800     0.1800     0.2671     2         
155      lemborexant    placebo -0.0485 0.0688     0.0688     0.2090     2         

Number of treatment arms (by study):
    narms
2       2
6       2
10      2
12      2
39      2
45      2
46      2
58      2
59      2
60      2
61      2
63      2
75      2
77      2
83      2
99      3
105     2
112     2
114     2
120     2
122     2
128     2
132     3
136     2
137     2
144     2
145     2
153     3
154     2
155     2

Results (fixed effects model):

              treat1     treat2     SMD             95%-CI     Q leverage
2            placebo   zolpidem  0.4058 [ 0.3373;  0.4742] 28.94     0.07
6        eszopiclone    placebo -0.2356 [-0.3148; -0.1564]  2.69     0.16
10           placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  1.70     0.10
12       eszopiclone    placebo -0.2356 [-0.3148; -0.1564]  0.01     0.01
39           placebo   zolpidem  0.4058 [ 0.3373;  0.4742] 23.85     0.07
45           placebo suvorexant  0.1627 [ 0.0456;  0.2799]  0.09     0.52
46           placebo suvorexant  0.1627 [ 0.0456;  0.2799]  0.10     0.48
58       eszopiclone    placebo -0.2356 [-0.3148; -0.1564]  0.20     0.24
59           placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  4.20     0.27
60           doxepin    placebo -0.1961 [-0.3619; -0.0303]  1.33     0.27
61           doxepin    placebo -0.1961 [-0.3619; -0.0303]  2.16     0.33
63           doxepin    placebo -0.1961 [-0.3619; -0.0303]  0.15     0.41
75           placebo  ramelteon -0.0600 [-0.2061;  0.0860]  0.24     0.63
77       eszopiclone    placebo -0.2356 [-0.3148; -0.1564]  0.17     0.10
83  BZD-intermediate    placebo -0.5278 [-0.8201; -0.2355]  1.95     0.16
99      daridorexant   zolpidem  0.2087 [-0.0132;  0.4307]  0.52        .
99           placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  0.52        .
99      daridorexant    placebo -0.1970 [-0.4190;  0.0249]  0.52        .
105          placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  0.05     0.06
112          placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  1.71     0.03
114          placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  1.08     0.06
120      eszopiclone    placebo -0.2356 [-0.3148; -0.1564]  0.32     0.09
122          placebo  zopiclone -0.0800 [-0.8288;  0.6687]  0.00     1.00
128 BZD-intermediate   zolpidem -0.1221 [-0.4087;  0.1646]  0.36     0.85
132          placebo  trazodone  0.2648 [ 0.0113;  0.5182]  0.16        .
132        trazodone   zolpidem  0.1410 [-0.1128;  0.3947]  0.17        .
132          placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  0.68        .
136      eszopiclone    placebo -0.2356 [-0.3148; -0.1564]  0.49     0.30
137          placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  1.70     0.06
144      eszopiclone    placebo -0.2356 [-0.3148; -0.1564]  2.47     0.11
145          placebo  ramelteon -0.0600 [-0.2061;  0.0860]  0.39     0.37
153      lemborexant   zolpidem  0.2698 [ 0.1676;  0.3720]  3.56        .
153          placebo   zolpidem  0.4058 [ 0.3373;  0.4742]  0.32        .
153      lemborexant    placebo -0.1359 [-0.2274; -0.0445]  0.73        .
154      lemborexant    placebo -0.1359 [-0.2274; -0.0445]  4.70     0.07
155      lemborexant    placebo -0.1359 [-0.2274; -0.0445]  1.62     0.46

Results (random effects model):

              treat1     treat2     SMD             95%-CI
2            placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
6        eszopiclone    placebo -0.2198 [-0.3968; -0.0428]
10           placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
12       eszopiclone    placebo -0.2198 [-0.3968; -0.0428]
39           placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
45           placebo suvorexant  0.1619 [-0.1357;  0.4594]
46           placebo suvorexant  0.1619 [-0.1357;  0.4594]
58       eszopiclone    placebo -0.2198 [-0.3968; -0.0428]
59           placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
60           doxepin    placebo -0.1999 [-0.4790;  0.0792]
61           doxepin    placebo -0.1999 [-0.4790;  0.0792]
63           doxepin    placebo -0.1999 [-0.4790;  0.0792]
75           placebo  ramelteon -0.0483 [-0.3601;  0.2635]
77       eszopiclone    placebo -0.2198 [-0.3968; -0.0428]
83  BZD-intermediate    placebo -0.5788 [-1.0161; -0.1414]
99      daridorexant   zolpidem  0.1968 [-0.2095;  0.6031]
99           placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
99      daridorexant    placebo -0.1851 [-0.5914;  0.2212]
105          placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
112          placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
114          placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
120      eszopiclone    placebo -0.2198 [-0.3968; -0.0428]
122          placebo  zopiclone -0.0800 [-0.9228;  0.7627]
128 BZD-intermediate   zolpidem -0.1968 [-0.6239;  0.2302]
132          placebo  trazodone  0.2543 [-0.1700;  0.6787]
132        trazodone   zolpidem  0.1276 [-0.2970;  0.5521]
132          placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
136      eszopiclone    placebo -0.2198 [-0.3968; -0.0428]
137          placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
144      eszopiclone    placebo -0.2198 [-0.3968; -0.0428]
145          placebo  ramelteon -0.0483 [-0.3601;  0.2635]
153      lemborexant   zolpidem  0.3077 [ 0.0452;  0.5701]
153          placebo   zolpidem  0.3819 [ 0.2435;  0.5204]
153      lemborexant    placebo -0.0742 [-0.3161;  0.1676]
154      lemborexant    placebo -0.0742 [-0.3161;  0.1676]
155      lemborexant    placebo -0.0742 [-0.3161;  0.1676]

Number of studies: k = 30
Number of pairwise comparisons: m = 36
Number of observations: o = 10745
Number of treatments: n = 11
Number of designs: d = 12

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI      z  p-value
BZD-intermediate -0.5278 [-0.8201; -0.2355]  -3.54   0.0004
daridorexant     -0.1970 [-0.4190;  0.0249]  -1.74   0.0819
doxepin          -0.1961 [-0.3619; -0.0303]  -2.32   0.0205
eszopiclone      -0.2356 [-0.3148; -0.1564]  -5.83 < 0.0001
lemborexant      -0.1359 [-0.2274; -0.0445]  -2.91   0.0036
placebo                .                  .      .        .
ramelteon         0.0600 [-0.0860;  0.2061]   0.81   0.4204
suvorexant       -0.1627 [-0.2799; -0.0456]  -2.72   0.0065
trazodone        -0.2648 [-0.5182; -0.0113]  -2.05   0.0406
zolpidem         -0.4058 [-0.4742; -0.3373] -11.62 < 0.0001
zopiclone         0.0800 [-0.6687;  0.8288]   0.21   0.8341

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value            95%-PI
BZD-intermediate -0.5788 [-1.0161; -0.1414] -2.59   0.0095 [-1.1965; 0.0390]
daridorexant     -0.1851 [-0.5914;  0.2212] -0.89   0.3719 [-0.7787; 0.4084]
doxepin          -0.1999 [-0.4790;  0.0792] -1.40   0.1603 [-0.7046; 0.3047]
eszopiclone      -0.2198 [-0.3968; -0.0428] -2.43   0.0149 [-0.6698; 0.2303]
lemborexant      -0.0742 [-0.3161;  0.1676] -0.60   0.5474 [-0.5569; 0.4084]
placebo                .                  .     .        .                 .
ramelteon         0.0483 [-0.2635;  0.3601]  0.30   0.7614 [-0.4774; 0.5740]
suvorexant       -0.1619 [-0.4594;  0.1357] -1.07   0.2864 [-0.6782; 0.3545]
trazodone        -0.2543 [-0.6787;  0.1700] -1.17   0.2401 [-0.8618; 0.3532]
zolpidem         -0.3819 [-0.5204; -0.2435] -5.41 < 0.0001 [-0.8166; 0.0528]
zopiclone         0.0800 [-0.7627;  0.9228]  0.19   0.8523 [-0.9011; 1.0612]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.0389; tau = 0.1973; I^2 = 74.4% [61.9%; 82.8%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                    Q d.f.  p-value
Total           89.87   23 < 0.0001
Within designs  74.36   18 < 0.0001
Between designs 15.51    5   0.0084
[1] "A total of 11 treatments are included in the network."
[1] "A total of 30 studies are included in this analysis."
[1] "A total of 10745 participants are included in this analysis."
[1] "The following studies were included in this analysis: 2 6 10 12 39 45 46 58 59 60 61 63 75 77 83 99 105 112 114 120 122 128 132 136 137 144 145 153 154 155"
[1] "Estimated heterogeneity tau-squared0.04"
[1] "Global test for inconsistency, p-value 0.00838 (Q=16, d.o.f. 5)"
[1] "File created on 2022-01-31"
